Results 231 to 240 of about 3,595,860 (302)

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

Inhibition of late sodium current prevents pathological hyperactivation of calcium/calmodulin‐dependent protein kinase IIδ in a murine model of acute doxorubicin‐related cardiotoxicity

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder   +7 more
wiley   +1 more source

Hydrophobic Tag Protein Degraders: An Emerging Therapeutic Strategy for Cancer. [PDF]

open access: yesPharmaceuticals (Basel)
Aguilera-Pineda T   +4 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira   +3 more
wiley   +1 more source

The c‐Src inhibitor eCF506 diminishes opioid tolerance and reduces β‐arrestin2 recruitment

open access: yesBritish Journal of Pharmacology, EarlyView.
Morphine activation of μ receptors causes tolerance through c‐Src activation and β‐arrestin2 recruitment. c‐Src inhibition or degradation reduces β‐arrestin2 recruitment, μ receptor endocytosis, while causing receptor upregulation, all likely contributing to reduced morphine tolerance.
Samuel Singleton   +6 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

open access: yesCancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi   +2 more
wiley   +1 more source

Structural dissection of the catalytic domain of the serine threonine kinase StkP of Streptococcus pneumoniae. [PDF]

open access: yesNat Commun
Hamidi M   +9 more
europepmc   +1 more source

LMTK2 Inhibits Metastasis of Colon Cancer Cells Through p38 MAPK

open access: yesCancer Science, EarlyView.
LMTK2 suppresses colon cancer metastasis by acting as a kinase‐independent scaffold that directly binds p38, blocking its interaction with MKK3/6 and subsequent phosphorylation, thereby inhibiting the downstream pro‐metastatic gene program. ABSTRACT Metastasis is the leading cause of death in patients with colon cancer. Although Lemur tyrosine kinase 2
Jie Lun   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy